株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

ペット向け癌治療の世界市場:成長、動向、および予測

Pet Cancer Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 704736
出版日 ページ情報 英文 118 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.06円で換算しております。
Back to Top
ペット向け癌治療の世界市場:成長、動向、および予測 Pet Cancer Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年09月01日 ページ情報: 英文 118 Pages
概要

当レポートは世界のペットの癌治療市場について調査しており、市場機会や課題、成長および阻害要因、治療・動物・用途・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の仮定
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 成長要因
  • 市場の阻害要因
  • ポーターのファイブフォース分析
    • 新規参入の脅威
    • バイヤー/消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 業界内の競争

第5章 市場セグメント

  • 治療別
    • 化学療法
    • 放射線療法
    • 免疫療法
    • その他
  • 動物別
    • その他
  • 用途別
    • リンパ腫
    • 肥満細胞癌
    • 黒色腫
    • 乳がんおよび扁平上皮癌
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ地域
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Elanco
    • AdvaVet Inc.
    • ELIAS Animal Health
    • Virbac
    • Boehringer Ingelheim GmbH (Merial)
    • Morphogenesis Inc.
    • Radiology Oncology Systems
    • Regeneus Ltd
    • VetDC Inc.
    • IDvet
    • Zoetis

第7章 市場機会および将来動向

目次
Product Code: 64177

Market Overview

The growing prevalence of several types of cancers in cats and dogs, as well as an increase in R&D initiatives regarding cancer management in animals, is contributing to the growth of the market. In addition to the aforementioned factor, growing pet health awareness and rise in R&D initiatives regarding pet cancer management are expected to propel market growth over the forecast period. However, side effects caused by drugs used for the treatment of pet cancers, the reluctance of pet owners to put their pet animals under medication is expected to restrain the pet cancer therapeutics market.

Scope of the Report

As per the scope, Cancer is one of the major causes of death in pets, mainly in dogs that are older than 10 years. However, according to experts, around half of all the prevalent cancers can be cured, if diagnosed early. The success rate of various treatments in preventing and curing neoplasia, and cancer in the pet population, has observed a significant rise over the past few years, as a result of the recent advancements in early recognition, diagnosis, and treatment.

Key Market Trends

Cancers in Dogs are Expected to Lead the Market

Dogs get cancer at about the same rate as humans, while cats get fewer cancers. Some breeds or families of dogs have a higher incidence for developing cancer at an earlier age, but in most cases, it's a disease found in aging animals. According to the Veterinary Cancer Society, cancer is the leading cause of death in 47% of dogs, especially those that are over age 10, and also in 32% of cats. In addition, the growing pet health awareness and a rise in the R&D initiatives regarding pet cancer management are expected to propel the market growth, over the forecast period. For instance, in April 2019 Elanco has signed a development and commercialization agreement with VetDC for Tanovea®-CA1, the first U.S. Food and Drug Administration (FDA) conditionally approved canine lymphoma treatment.

North America Dominates the Pet Cancer Therapeutics Market

North America is expected to retain its significant market share, owing to factors, such as rising pet adoption and increasing per capita animal healthcare expenditure. In addition, the rise in the prevalence of various animal diseases and injuries has been identified as the major factor fueling market growth. Approximately, 90 million dogs are owned in the United States, as per reported by the American Pet Products Association (APPA). In addition, the data published by APPA, in 2019, stated that the total pet healthcare expenditure is estimated to be USD 75.38 billion by the end of the year, while the expenditure in 2018 was USD 72.56 billion. North America also emphasizes on establishing proper skills among veterinary practitioners. Hence, all these factors are driving the growth of the pet cancer therapeutics market in North America.

Competitive Landscape

The market players in the pet cancer therapeutics market are involving in various growth strategies such as collaborations, partnerships, agreements, mergers and acquisitions in order to enhance the market presence. For instance, In April 2019, Elanco Animal Health has signed an agreement to acquire Aratana Therapeutics, pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats and in Jan 2018, Aratana Therapeutics was granted conditional approval for its canine osteosarcoma vaccine, live Listeria vector (AT-014), by the USDA's Center for Veterinary Biologics.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in R&D Initiatives for Cancer Management
    • 4.2.2 High Prevalence of Cancer in Pets
    • 4.2.3 High Prevalence of Cancer in Pets
  • 4.3 Market Restraints
    • 4.3.1 Side Effects Associated with Pet Cancer Therapy
    • 4.3.2 High Cost of Treatment
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Therapy
    • 5.1.1 Chemotherapy
    • 5.1.2 Radiation therapy
    • 5.1.3 Immunotherapy
    • 5.1.4 Other Therapies
  • 5.2 By Animal
    • 5.2.1 Dog
    • 5.2.2 Cat
    • 5.2.3 Other Animals
  • 5.3 By Application
    • 5.3.1 Lymphoma
    • 5.3.2 Mast Cell Cancer
    • 5.3.3 Melanoma
    • 5.3.4 Mammary and Squamous Cell Cancer
    • 5.3.5 Other Applications
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 US
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 UK
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Elanco
    • 6.1.2 AdvaVet Inc.
    • 6.1.3 ELIAS Animal Health
    • 6.1.4 Virbac
    • 6.1.5 Boehringer Ingelheim GmbH (Merial)
    • 6.1.6 Morphogenesis Inc.
    • 6.1.7 Radiology Oncology Systems
    • 6.1.8 Regeneus Ltd
    • 6.1.9 VetDC Inc.
    • 6.1.10 IDvet
    • 6.1.11 Zoetis

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top